Aurora Kinase A Confers Drug Resistance to Breast Cancer Cells, Lab Study Shows

Aurora Kinase A Confers Drug Resistance to Breast Cancer Cells, Lab Study Shows
Using a novel systematic method, scientists found that breast cancer cells use Aurora kinase A to evade being targeted by drugs inhibiting the PI3K pathway. Blocking this protein restores the therapeutic potential of previous ineffective cancer therapies. The study with that finding, "Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer," was published recently in Nature Chemical Biology. More than 60 percent of breast cancer cases involve defects in the PI3 kinase (PI3K) pathway, which is a biochemical cascade that spurs the growth and survival of cancer cells when abnormally activated. While this has made PI3K a promising pharmaceutical target for several types of tumors, the clinical effectiveness of PI3K inhibitors for cancer treatment achieved little success in previous trials, leaving researchers with no clue to account for its failure. “The failure of PI3 kinase drugs has been a huge mystery,” Sourav Bandyopadhyay, PhD, said in a press release. Bandyopadhyay is assistant professor of bioengineering and therapeutic sciences and a faculty member of the UCSF Helen Diller Family Comprehensive Cancer Center, . Even Novartis’s Afinitor (everolimus) — an inhibitor of the mTOR kinase that also is involved in the PI3K pathway and was approved by the U.S. Food and Drug Administration for the treat
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.